Bio-Techne(US:TECH) Prnewswire·2025-04-23 11:00Core Insights - Bio-Techne Corporation will showcase its advancements in cancer research tools at the 2025 AACR Annual Meeting, highlighting its oncology research portfolio [1][2] Group 1: Company Overview - Bio-Techne is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostics, generating approximately $1.2 billion in net sales in fiscal 2024 [10] - The company has around 3,100 employees worldwide and offers a comprehensive portfolio of products to assist in scientific investigations and drug discovery [10] Group 2: Event Participation - At the AACR Annual Meeting, Bio-Techne will engage with researchers and industry professionals to present its cutting-edge solutions that support advancements in oncology [2] - The company will feature its oncology research portfolio at booth 3049, including high-performance proteins, antibodies, small molecules, and automated proteomic analysis platforms [3] Group 3: Specific Technologies and Presentations - Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will showcase its protease-free workflows for spatial multiomic research, enhancing capabilities for multiomic detection [3] - Lunaphore, another Bio-Techne brand, will present its fully-automated multiomics application for fixed-frozen tissue and host an exclusive dinner reception for the spatial biology community [4] Group 4: Research Presentations - Bio-Techne will conduct several poster presentations at the AACR, including topics such as protein quantitation for cancer therapeutics and multiomic co-detection in tumor microenvironments [6][7][8] - Specific presentations will cover evaluations of biomarkers in glioblastoma and immune cell phenotypes in various cancer types [6][8][9]